Fundamental Analysis of PROTARA THERAPEUTIC INC(NASDAQ:TARA) stock

Fundamental Rating

Overall TARA gets a fundamental rating of 3 out of 10. We evaluated TARA against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TARA as it has an excellent financial health rating, but there are worries on the profitability. TARA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

TARA had negative earnings in the past year.

TARA had a negative operating cash flow in the past year.

TARA had negative earnings in each of the past 5 years.

TARA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -44.69%, TARA is in line with its industry, outperforming 51.68% of the companies in the same industry.

The Return On Equity of TARA (-51.41%) is better than 66.19% of its industry peers.

		Industry Rank	Sector Rank
ROA	-44.69%
ROE	-51.41%
ROIC	N/A

ROA(3y)-45.59%

ROA(5y)-73.53%

ROE(3y)-50.98%

ROE(5y)-80.84%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TARA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TARA has more shares outstanding than it did 1 year ago.

TARA has more shares outstanding than it did 5 years ago.

TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TARA has an Altman-Z score of 1.57. This is a bad value and indicates that TARA is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 1.57, TARA is in the better half of the industry, outperforming 68.32% of the companies in the same industry.

There is no outstanding debt for TARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1.57

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

TARA has a Current Ratio of 9.85. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 9.85, TARA belongs to the best of the industry, outperforming 80.35% of the companies in the same industry.

A Quick Ratio of 9.85 indicates that TARA has no problem at all paying its short term obligations.

TARA has a better Quick ratio (9.85) than 80.53% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.85
Quick Ratio	9.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.18% over the past year.

EPS 1Y (TTM)33.18%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%42.53%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

TARA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.09% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y12%

EPS Next 2Y3.79%

EPS Next 3Y9.43%

EPS Next 5Y10.09%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.79%

EPS Next 3Y9.43%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TARA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTARA THERAPEUTIC INC

NASDAQ:TARA (12/18/2024, 4:30:01 PM)

After market: 5.24 +0.08 (+1.55%)

5.16

-0.46 (-8.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap106.45M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-44.69%
ROE	-51.41%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	9.85
Quick Ratio	9.85
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)33.18%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y12%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROTARA THERAPEUTIC INC (TARA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens